<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="299">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157256</url>
  </required_header>
  <id_info>
    <org_study_id>2021_HEMOGLOB-VAX_COVID19</org_study_id>
    <nct_id>NCT05157256</nct_id>
  </id_info>
  <brief_title>Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination in a Cohort of Patients With Thalassemic and Falcemic Syndromes</brief_title>
  <acronym>HEMOGLOB-VAX</acronym>
  <official_title>Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination in a Cohort of Patients With Thalassemic and Falcemic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Società Italiana Talassemie ed Emoglobinopatie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Società Italiana Talassemie ed Emoglobinopatie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is an urgent need to rapidly evaluate anti-Covid 19 vaccination treatments, in terms of&#xD;
      immune response (humoral and cell-mediated) together with the verification of the&#xD;
      effectiveness of the vaccine in preventing SARS-CoV-2 infection in thalassemic subjects.&#xD;
&#xD;
      It is also necessary to increase scientific knowledge in order to improve clinical practice&#xD;
      to have presence responses and maintenance extent of the response to vaccinations against&#xD;
      encapsulated bacteria carried out previously.&#xD;
&#xD;
      The objectives of the main study are:&#xD;
&#xD;
        1. Evaluate the appearance, extent, and duration of humoral response (antibodies) to the&#xD;
           anti-SARS-CoV-2 vaccine;&#xD;
&#xD;
        2. Assess the incidence of positive cases after vaccination.&#xD;
&#xD;
      The objective of the first sub-study is:&#xD;
&#xD;
      - Evaluate the appearance, extent, and duration of cellular response (T lymphocytes and B&#xD;
      lymphocytes) to the anti-SARS-CoV-2 vaccine based on age groups and the presence/absence of&#xD;
      hypo/asplenia.&#xD;
&#xD;
      The objective of the second sub-study is:&#xD;
&#xD;
      - Evaluate the presence and extent of the response to previous vaccinations to encapsulated&#xD;
      bacteria.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-profit multicenter observational study, coordinated by the Department of&#xD;
      OncoHematology,Cell Therapy, Gene Therapies and Hematopoietic Transplantation of the Bambino&#xD;
      Gesù Children'sHospital, IRCCS which provides for the collectionof clinical data of patients&#xD;
      with an established diagnosis of TDT and SCD after the administration of the&#xD;
      anti-SARS-CoV-2vaccine.&#xD;
&#xD;
      As this is a prospective study for medium-term assessments, it is expected to last no less&#xD;
      than 18 months. The duration of the prospective observation will start from April 2021 for&#xD;
      the duration of 12 months.&#xD;
&#xD;
      Setting&#xD;
&#xD;
      The following will be enrolled:&#xD;
&#xD;
        -  for the main study patients diagnosed with TDT and SCD even if they have previously&#xD;
           contracted SARS-CoV-2 infection;&#xD;
&#xD;
        -  for the first substudy, patients with TDT and SCD diagnosis will be enrolled, divided by&#xD;
           presence/absence of hypo/asplenia;&#xD;
&#xD;
        -  for the second substudy, patients diagnosed with TDT and hypo/asplenic SCD will be&#xD;
           enrolled.&#xD;
&#xD;
      The Scientific Committee of the project discussed and approved a dataset that will be&#xD;
      collected by local centers, the pseudo-anonymized data of patients collected in a special&#xD;
      e-CRF.&#xD;
&#xD;
      The participating centers are:&#xD;
&#xD;
      - Rome, Brindisi, Cagliari, Genoa, Ferrara, Milan, Naples, Palermo Turin, Verona.&#xD;
&#xD;
      The Italian Society of Thalassemia and Hemoglobinopathies (SITE) in its role as a scientific&#xD;
      society of reference for the pathology will act as Promoter of the experimentation and the&#xD;
      ForAnemia Foundation, a non-profit organization, is also identified as a funder of the&#xD;
      present study.&#xD;
&#xD;
      The project will be developed through the creation and validation of a data collection card&#xD;
      in which the clinical data relating to all patients with the characteristics of inclusion in&#xD;
      the participating centers will be entered.&#xD;
&#xD;
      The data to be entered include characteristics of the patient, in addition to epidemiological&#xD;
      data (sex, age) and clinical data (diagnosis), pre-existing comorbidities, indication of iron&#xD;
      overload, drugs administered. Data analysis will be primarily descriptive.&#xD;
&#xD;
      It is accepted in advance that this protocol may require repeated modifications to conform to&#xD;
      the evolution of knowledge about the pandemic, the complication rate and the therapeutic&#xD;
      scenario. A high degree of adaptation is therefore expected, which will be rigorously&#xD;
      discussed with the independent data monitoring committee that will be appointed immediately&#xD;
      after the approval of the protocol.&#xD;
&#xD;
      Study population Patients with TDT and SCD. Inclusion criteria&#xD;
&#xD;
      Main study and first substudy:&#xD;
&#xD;
        -  Patients with advancedTDT and SCD diagnosis, age &gt; 18 years&#xD;
&#xD;
        -  signature of informed consent.&#xD;
&#xD;
      Second substudy:&#xD;
&#xD;
        -  Splenectomized patients withTDT and SCD diagnosed, age &gt; 18 years&#xD;
&#xD;
        -  signature of informed consent. Exclusion criteria No signature informed consent. Results&#xD;
           of the Study&#xD;
&#xD;
      The following variables will be measured:&#xD;
&#xD;
        -  anti_N Antibody Value&#xD;
&#xD;
        -  Anti-RBD values&#xD;
&#xD;
        -  memory andi-trimeric Spike IgG in total memory (% of total IgG memory)&#xD;
&#xD;
        -  Immunity value T (IFN-g) Variables Samples for the analysis of humoral and cell-mediated&#xD;
           response will be collected before vaccination (T0), at booster (T1), between 14 and 21&#xD;
           days after recall (T2) and after 12, 24 and 52 weeks after vaccination.&#xD;
&#xD;
      Sampling before vaccination (T0) can be collected up to 5 days before vaccination. Sampling&#xD;
      prior to administration of the booster (T1) may be collected up to 5 days in advance.&#xD;
&#xD;
      Withdrawals at weeks 12, 24, 52 will be performed with a tolerance of 10 days.&#xD;
&#xD;
      - The analysis of the presence of specific antibodies (IgG) to N and S viral antigens will be&#xD;
      carried out by CMIA method. The analysis of both antibodies will allow to evaluate the&#xD;
      response to the vaccine (anti-S antibodies) and a possible natural exposure/infection (anti-N&#xD;
      antibodies). In patients who present anti-S antibodies, neutralizing titiness measurement&#xD;
      will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the appearance, extent, and duration of humoral response (antibodies) to the anti-SARS-CoV-2 vaccine;</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the incidence of positive cases after vaccination.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>- Evaluate the appearance, extent and duration of cellular response (T lymphocytes and B lymphocytes) to the anti-SARS-CoV-2 vaccine based on age groups and the presence/absence of hypo/asplenia</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the presence and extent of the response to previous vaccinations to encapsulated bacteria.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>SARS-CoV-2 Infection, Thalasemmie, SCD</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with TDT and SCD.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria&#xD;
&#xD;
        Main study and first substudy:&#xD;
&#xD;
          -  Patients with advancedTDT and SCD diagnosis, age &gt; 18 years&#xD;
&#xD;
          -  signature of informed consent.&#xD;
&#xD;
        Second substudy:&#xD;
&#xD;
          -  Splenectomized patients withTDT and SCD diagnosed, age &gt; 18 years&#xD;
&#xD;
          -  signature of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        No signature informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonia Gigante</last_name>
    <phone>+393888179978</phone>
    <email>antonia.gigante@foranemia.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Torino, Italia</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filomena Longo</last_name>
      <phone>39 011 9026032</phone>
      <email>filomena.longo@unito.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Barella, MD</last_name>
      <phone>+39 070 6095655</phone>
      <phone_ext>-518</phone_ext>
      <email>susannabarella@asl8cagliari.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Day Hospital della Talassemia e delle Emoglobinopatie - A.O.U. di Ferrara - Nuovo Ospedale S.Anna - Sede di Cona</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rita Gamberini</last_name>
      <phone>39 0532 236402</phone>
      <email>m.gamberini@ospfe.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Galliera - S.S.D. Microcitemia, anemie congenite e dismetabolismo del ferro</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Luca Forni, MD</last_name>
      <phone>+390105634560</phone>
      <email>gianluca.forni@galliera.it</email>
    </contact>
    <investigator>
      <last_name>Valeria M Pinto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanna Graziadei</last_name>
      <phone>39 02 55033358</phone>
      <email>giovanna_graziadei@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Women, Children and General and Specialist Surgery AOU-- University of Campania &quot;Luigi Vanvitelli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silverio Perrotta</last_name>
      <phone>39 081 5565421</phone>
      <email>silverio.perrotta@unicampania.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Ematologia e Malattie Rare del Sangue e degli Organi Ematopoietici - Azienda Ospedaliera Ospedali Riuniti &quot;Villa Sofia-Cervello&quot; - Presidio Cervello</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelio Maggio</last_name>
      <phone>39 091 6802841</phone>
      <email>md.amaggio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento OncoEmatologia, Terapia Cellulare, Terapie Geniche e Trapianto Emopoietico</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli</last_name>
      <phone>39 06 68592129</phone>
      <email>franco.locatelli@opbg.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia De Franceschi, MD</last_name>
      <phone>39 045 8074403</phone>
      <email>lucia.defranceschi@univr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 10, 2021</study_first_submitted>
  <study_first_submitted_qc>December 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 10, 2021</last_update_submitted>
  <last_update_submitted_qc>December 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

